Dr. Reddy's Laboratories launches Versavo in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
It is the first autotaxin inhibitor to be investigated in cancer patients
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
With just few days of treatment, the patient started responding well and finally complete clinical resolution of infection was attained
Subscribe To Our Newsletter & Stay Updated